Actavis Inc (ACT) 239.03 $ACT
3 Generics Stocks to Buy Now - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Oct 28, 9:28AM CDT
Data from IMS health show that 29% of expenditure on prescription drugs in the U.S. can be attributed to generics.
MNK: 93.74 (+2.81), ABT: 42.50 (+0.26), ACT: 239.03 (+0.60), MYL: 51.71 (+0.76), ABBV: 60.93 (+0.44)
Lannett Co. Gets Growth Rx In Generic Drugs Group
at Investor's Business Daily - Mon Oct 27, 4:59PM CDT
Generic-drug maker Lannett Co. boasts a robust pipeline and has its sights on growing revenue substantially over the next several years. The Philadelphia-based company is already on solid footing. In late August, it reported fiscal 2014...
LCI: 53.16 (+1.70), PRGO: 156.17 (+1.36), ACT: 239.03 (+0.60), AKRX: 43.54 (-0.73), TEVA: 54.80 (+0.80)
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:40PM CDT
Aegerion has an Earnings ESP of -25.00% and carries a Zacks Rank #3.
ACT: 239.03 (+0.60), VRTX: 114.07 (+2.48), TEVA: 54.80 (+0.80), AEGR: 33.69 (+1.50)
Will Growth Measures Reflect on Aetna (AET) Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 1:21PM CDT
Aetna Inc. (AET) is scheduled to report Q3 earnings results before the opening bell on Oct 28.
CI: 92.58 (-0.07), ACT: 239.03 (+0.60), AET: 77.23 (-1.95), MGLN: 59.49 (+0.50)
The Medicines Co.'s Q3 Earnings Fall Y/Y, Guidance Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 12:00PM CDT
The Medicines Co. reported earnings of 5 cents per share in the third quarter of 2014, compared to the year-ago earnings of 38 cents per share.
ACT: 239.03 (+0.60), MDCO: 25.86 (+3.67), MYL: 51.71 (+0.76), HSP: 52.30 (+0.57)
Video: Allergan Lifts Views; Valeant Suggests Higher Bid
at Investor's Business Daily - Mon Oct 27, 11:17AM CDT
Specialty drugmaker Allergan (AGN) reported solid Q3 results and raised its guidance Monday, as hostile suitor Valeant Pharmaceuticals International (VRX) said that it might raise its bid for the company again. Allergan's Q3 earnings rose 45% over...
AGN: 182.60 (+0.27), ACT: 239.03 (+0.60), VRX: 131.07 (+0.51), SHPG: 197.80 (+1.93), ABBV: 60.93 (+0.44)
Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 3:11PM CDT
Vertex Pharmaceuticals (VRTX) is likely to beat earnings expectations in the third quarter of 2014.
ACT: 239.03 (+0.60), VRTX: 114.07 (+2.48), LGND: 51.89 (-2.34), TEVA: 54.80 (+0.80)
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:48PM CDT
Epizyme, Inc. (EPZM) has an earnings ESP of 0.00% and a Zacks Rank #3 (Hold).
ACT: 239.03 (+0.60), LGND: 51.89 (-2.34), TEVA: 54.80 (+0.80), EPZM: 28.00 (+0.62)
Stock Charts Show Stocks' Health, Optimal Buy Point
at Investor's Business Daily - Thu Oct 23, 4:54PM CDT
If a picture is worth a thousand words, a stock chart carries just as much weight for investors -- if not more. Stock charts not only provide a wealth of information but can also help investors figure out if a stock is outperforming or...
ACT: 239.03 (+0.60)
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent
PR Newswire - Thu Oct 23, 7:00AM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals' Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). Lo Loestrin® Fe is a prescription birth control pill used for the prevention of pregnancy.
ACT: 239.03 (+0.60)
Illumina Breaks Out Of Double-Bottom Base
at Investor's Business Daily - Wed Oct 22, 4:53PM CDT
With the market again in an uptrend, investors should put money to work in leading stocks. A number of issues on Stock Spotlight are in buying range. Illumina (ILMN) is in buy range after rising past an 182.37 entry from a double-bottom base and...
LCI: 53.16 (+1.70), ACT: 239.03 (+0.60), FB: 80.77 (+0.49), ILMN: 190.65 (-0.66)
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix
PR Newswire - Wed Oct 22, 8:10AM CDT
Today, Analysts Review released its research reports regarding UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7391-100free.
ACT: 239.03 (+0.60), UNH: 92.64 (+0.51), SLXP: 139.94 (+2.10), BMY: 54.20 (+0.67), CELG: 105.70 (+2.60), CELGZ: 3.56 (-0.03)
Akorn (AKRX) Looks Good: Stock Adds 5.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:04AM CDT
Akorn, Inc. (AKRX) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
IPXL: 27.96 (-0.18), ACT: 239.03 (+0.60), AKRX: 43.54 (-0.73), MYL: 51.71 (+0.76)
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
PR Newswire - Wed Oct 22, 7:30AM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health, Inc., which is developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other GI functional disorders.
ACT: 239.03 (+0.60)
PEG Ratio vs. the P/E Ratio - Screen of the Week
Kevin Matras - ZACKS - Tue Oct 21, 3:14AM CDT
PEG Ratio vs. the P/E Ratio - Screen of the Week
LCI: 53.16 (+1.70), ACT: 239.03 (+0.60), ALDW: 18.45 (+0.03), TTM: 46.61 (+1.75), UAL: 52.36 (+0.63)
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings
at Investor's Business Daily - Mon Oct 20, 5:01PM CDT
Pharmaceutical stocks continue to assert a comparatively steady influence on a correcting market. They held four of 16 slots among Stock Spotlight issues on Monday, two biotechs and two makers of generic drugs. Chart-wise, Akorn Pharmaceuticals...
ACT: 239.03 (+0.60), GILD: 113.45 (+0.86), AKRX: 43.54 (-0.73), ALXN: 192.20 (+1.65)
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt
PR Newswire - Mon Oct 20, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Mallinckrodt PLC (NYSE: MNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 17, 2014, the NASDAQ Composite ended at 4,258.44, up 0.97%, the Dow Jones Industrial Average advanced 1.63%, to finish the day at 16,380.41, and the S&P 500 closed at 1,886.76, up 1.29%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index also advancing 0.29% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MNK: 93.74 (+2.81), ZTS: 37.01 (+0.44), AGN: 182.60 (+0.27), AVNR: 11.84 (-0.01), ACT: 239.03 (+0.60)
Akorn Finds Institutional Support In Base
at Investor's Business Daily - Fri Oct 17, 5:36PM CDT
Market corrections give leading stocks a chance to take a break from prior run-ups and forge sound bases before attempting to resume their climb. Akorn (AKRX) is following this script. The drugmaker's stock is starting the eighth week of a new base...
ACT: 239.03 (+0.60), AKRX: 43.54 (-0.73)
3 Generics Stocks to Buy Now - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Oct 28, 9:28AM CDT
Data from IMS health show that 29% of expenditure on prescription drugs in the U.S. can be attributed to generics.
MNK: 93.74 (+2.81), ABT: 42.50 (+0.26), ACT: 239.03 (+0.60), MYL: 51.71 (+0.76), ABBV: 60.93 (+0.44)
Lannett Co. Gets Growth Rx In Generic Drugs Group
at Investor's Business Daily - Mon Oct 27, 4:59PM CDT
Generic-drug maker Lannett Co. boasts a robust pipeline and has its sights on growing revenue substantially over the next several years. The Philadelphia-based company is already on solid footing. In late August, it reported fiscal 2014...
LCI: 53.16 (+1.70), PRGO: 156.17 (+1.36), ACT: 239.03 (+0.60), AKRX: 43.54 (-0.73), TEVA: 54.80 (+0.80)
Will Aegerion (AEGR) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:40PM CDT
Aegerion has an Earnings ESP of -25.00% and carries a Zacks Rank #3.
ACT: 239.03 (+0.60), VRTX: 114.07 (+2.48), TEVA: 54.80 (+0.80), AEGR: 33.69 (+1.50)
Will Growth Measures Reflect on Aetna (AET) Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 1:21PM CDT
Aetna Inc. (AET) is scheduled to report Q3 earnings results before the opening bell on Oct 28.
CI: 92.58 (-0.07), ACT: 239.03 (+0.60), AET: 77.23 (-1.95), MGLN: 59.49 (+0.50)
The Medicines Co.'s Q3 Earnings Fall Y/Y, Guidance Lowered - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 12:00PM CDT
The Medicines Co. reported earnings of 5 cents per share in the third quarter of 2014, compared to the year-ago earnings of 38 cents per share.
ACT: 239.03 (+0.60), MDCO: 25.86 (+3.67), MYL: 51.71 (+0.76), HSP: 52.30 (+0.57)
Video: Allergan Lifts Views; Valeant Suggests Higher Bid
at Investor's Business Daily - Mon Oct 27, 11:17AM CDT
Specialty drugmaker Allergan (AGN) reported solid Q3 results and raised its guidance Monday, as hostile suitor Valeant Pharmaceuticals International (VRX) said that it might raise its bid for the company again. Allergan's Q3 earnings rose 45% over...
AGN: 182.60 (+0.27), ACT: 239.03 (+0.60), VRX: 131.07 (+0.51), SHPG: 197.80 (+1.93), ABBV: 60.93 (+0.44)
Will Vertex Pharmaceuticals (VRTX) Post a Lower Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 3:11PM CDT
Vertex Pharmaceuticals (VRTX) is likely to beat earnings expectations in the third quarter of 2014.
ACT: 239.03 (+0.60), VRTX: 114.07 (+2.48), LGND: 51.89 (-2.34), TEVA: 54.80 (+0.80)
Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:48PM CDT
Epizyme, Inc. (EPZM) has an earnings ESP of 0.00% and a Zacks Rank #3 (Hold).
ACT: 239.03 (+0.60), LGND: 51.89 (-2.34), TEVA: 54.80 (+0.80), EPZM: 28.00 (+0.62)
Stock Charts Show Stocks' Health, Optimal Buy Point
at Investor's Business Daily - Thu Oct 23, 4:54PM CDT
If a picture is worth a thousand words, a stock chart carries just as much weight for investors -- if not more. Stock charts not only provide a wealth of information but can also help investors figure out if a stock is outperforming or...
ACT: 239.03 (+0.60)
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent
PR Newswire - Thu Oct 23, 7:00AM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals' Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). Lo Loestrin® Fe is a prescription birth control pill used for the prevention of pregnancy.
ACT: 239.03 (+0.60)
Illumina Breaks Out Of Double-Bottom Base
at Investor's Business Daily - Wed Oct 22, 4:53PM CDT
With the market again in an uptrend, investors should put money to work in leading stocks. A number of issues on Stock Spotlight are in buying range. Illumina (ILMN) is in buy range after rising past an 182.37 entry from a double-bottom base and...
LCI: 53.16 (+1.70), ACT: 239.03 (+0.60), FB: 80.77 (+0.49), ILMN: 190.65 (-0.66)
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix
PR Newswire - Wed Oct 22, 8:10AM CDT
Today, Analysts Review released its research reports regarding UnitedHealth Group Inc. (NYSE: UNH), Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY) and Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7391-100free.
ACT: 239.03 (+0.60), UNH: 92.64 (+0.51), SLXP: 139.94 (+2.10), BMY: 54.20 (+0.67), CELG: 105.70 (+2.60), CELGZ: 3.56 (-0.03)
Akorn (AKRX) Looks Good: Stock Adds 5.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:04AM CDT
Akorn, Inc. (AKRX) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
IPXL: 27.96 (-0.18), ACT: 239.03 (+0.60), AKRX: 43.54 (-0.73), MYL: 51.71 (+0.76)
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
PR Newswire - Wed Oct 22, 7:30AM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health, Inc., which is developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other GI functional disorders.
ACT: 239.03 (+0.60)
PEG Ratio vs. the P/E Ratio - Screen of the Week
Kevin Matras - ZACKS - Tue Oct 21, 3:14AM CDT
PEG Ratio vs. the P/E Ratio - Screen of the Week
LCI: 53.16 (+1.70), ACT: 239.03 (+0.60), ALDW: 18.45 (+0.03), TTM: 46.61 (+1.75), UAL: 52.36 (+0.63)
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings
at Investor's Business Daily - Mon Oct 20, 5:01PM CDT
Pharmaceutical stocks continue to assert a comparatively steady influence on a correcting market. They held four of 16 slots among Stock Spotlight issues on Monday, two biotechs and two makers of generic drugs. Chart-wise, Akorn Pharmaceuticals...
ACT: 239.03 (+0.60), GILD: 113.45 (+0.86), AKRX: 43.54 (-0.73), ALXN: 192.20 (+1.65)
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt
PR Newswire - Mon Oct 20, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), and Mallinckrodt PLC (NYSE: MNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 17, 2014, the NASDAQ Composite ended at 4,258.44, up 0.97%, the Dow Jones Industrial Average advanced 1.63%, to finish the day at 16,380.41, and the S&P 500 closed at 1,886.76, up 1.29%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index also advancing 0.29% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MNK: 93.74 (+2.81), ZTS: 37.01 (+0.44), AGN: 182.60 (+0.27), AVNR: 11.84 (-0.01), ACT: 239.03 (+0.60)
Akorn Finds Institutional Support In Base
at Investor's Business Daily - Fri Oct 17, 5:36PM CDT
Market corrections give leading stocks a chance to take a break from prior run-ups and forge sound bases before attempting to resume their climb. Akorn (AKRX) is following this script. The drugmaker's stock is starting the eighth week of a new base...
ACT: 239.03 (+0.60), AKRX: 43.54 (-0.73)
